The oncogenic role of Ezrin is not limited to solid tumors as it has also been seen in blood cancers, such as diffuse large B-cell lymphoma, where the knockdown of Ezrin attenuated chemotherapy resistance (Pore et al., 2015; Sun et al., 2018). The gene discussed is EZR; the disease is diffuse large B-cell lymphoma.